AAPL   330.76 (+2.62%)
MSFT   186.96 (+2.21%)
FB   230.61 (+1.91%)
CGC   16.51 (-0.72%)
BABA   219.49 (+0.67%)
MU   54.04 (+5.49%)
GE   7.90 (+2.07%)
TSLA   883.85 (+2.25%)
AMD   53.09 (+0.87%)
T   32.86 (+3.30%)
ACB   13.90 (-2.32%)
GILD   76.88 (-0.85%)
DIS   124.55 (+0.70%)
BAC   28.11 (+4.97%)
BA   205.09 (+11.28%)
AAPL   330.76 (+2.62%)
MSFT   186.96 (+2.21%)
FB   230.61 (+1.91%)
CGC   16.51 (-0.72%)
BABA   219.49 (+0.67%)
MU   54.04 (+5.49%)
GE   7.90 (+2.07%)
TSLA   883.85 (+2.25%)
AMD   53.09 (+0.87%)
T   32.86 (+3.30%)
ACB   13.90 (-2.32%)
GILD   76.88 (-0.85%)
DIS   124.55 (+0.70%)
BAC   28.11 (+4.97%)
BA   205.09 (+11.28%)
AAPL   330.76 (+2.62%)
MSFT   186.96 (+2.21%)
FB   230.61 (+1.91%)
CGC   16.51 (-0.72%)
BABA   219.49 (+0.67%)
MU   54.04 (+5.49%)
GE   7.90 (+2.07%)
TSLA   883.85 (+2.25%)
AMD   53.09 (+0.87%)
T   32.86 (+3.30%)
ACB   13.90 (-2.32%)
GILD   76.88 (-0.85%)
DIS   124.55 (+0.70%)
BAC   28.11 (+4.97%)
BA   205.09 (+11.28%)
AAPL   330.76 (+2.62%)
MSFT   186.96 (+2.21%)
FB   230.61 (+1.91%)
CGC   16.51 (-0.72%)
BABA   219.49 (+0.67%)
MU   54.04 (+5.49%)
GE   7.90 (+2.07%)
TSLA   883.85 (+2.25%)
AMD   53.09 (+0.87%)
T   32.86 (+3.30%)
ACB   13.90 (-2.32%)
GILD   76.88 (-0.85%)
DIS   124.55 (+0.70%)
BAC   28.11 (+4.97%)
BA   205.09 (+11.28%)
Log in

LON:DESTDestiny Pharma Share Price, Forecast & News

GBX 38.50
+3.00 (+8.45 %)
(As of 06/5/2020 03:31 PM ET)
Add
Compare
Today's Range
35.15
Now: GBX 38.50
39.90
50-Day Range
32.50
MA: GBX 36.26
44
52-Week Range
30
Now: GBX 38.50
80
Volume51,704 shs
Average Volume4,205 shs
Market Capitalization£16.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections. The company has collaboration agreement with China Medical System Holdings Limited; and research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis. The company was incorporated in 1996 and is headquartered in Brighton, the United Kingdom.
Read More
Destiny Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1273-704440

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£305,906.00
Cash FlowGBX 17.79 per share
Book ValueGBX 17.70 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£16.89 million
Next Earnings DateN/A
OptionableOptionable

Receive DEST News and Ratings via Email

Sign-up to receive the latest news and ratings for DEST and its competitors with MarketBeat's FREE daily newsletter.

Destiny Pharma (LON:DEST) Frequently Asked Questions

How has Destiny Pharma's stock been impacted by COVID-19 (Coronavirus)?

Destiny Pharma's stock was trading at GBX 35.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DEST shares have increased by 8.5% and is now trading at GBX 38.50. View which stocks have been most impacted by Coronavirus.

How were Destiny Pharma's earnings last quarter?

Destiny Pharma PLC (LON:DEST) announced its earnings results on Wednesday, April, 29th. The company reported ($10.70) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($11.90) by $1.20. View Destiny Pharma's earnings history.

Has Destiny Pharma been receiving favorable news coverage?

News articles about DEST stock have been trending positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Destiny Pharma earned a coverage optimism score of 2.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutDestiny Pharma.

Who are some of Destiny Pharma's key competitors?

What other stocks do shareholders of Destiny Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include Abbott Laboratories (ABT), African Potash (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), Walt Disney (DIS), Enbridge (ENB), FDM Group (FDM), First Solar (FSLR), Fortress Transprtn and Infr Investrs (FTAI) and Intel (INTC).

Who are Destiny Pharma's key executives?

Destiny Pharma's management team includes the following people:
  • Mr. Neil Robert Clark, CEO & Director (Age 56)
  • Dr. William Guy Love, Founder, Chief Scientific Officer & Director (Age 56)
  • Mr. Shaun Claydon, CFO, Company Sec. & Director (Age 51)
  • Dr. Jesús M González Moreno, Chief Medical Officer

What is Destiny Pharma's stock symbol?

Destiny Pharma trades on the London Stock Exchange (LON) under the ticker symbol "DEST."

How do I buy shares of Destiny Pharma?

Shares of DEST and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Destiny Pharma's stock price today?

One share of DEST stock can currently be purchased for approximately GBX 38.50.

How big of a company is Destiny Pharma?

Destiny Pharma has a market capitalization of £16.89 million and generates £305,906.00 in revenue each year.

What is Destiny Pharma's official website?

The official website for Destiny Pharma is www.destinypharma.com.

How can I contact Destiny Pharma?

Destiny Pharma's mailing address is Sussex Innovation Centre Science Park Square, Falmer, BRIGHTON, BN1 9SB, United Kingdom. The company can be reached via phone at +44-1273-704440.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.